Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Cardiovasc Pharmacol ; 62(2): 205-11, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23615158

RESUMEN

BACKGROUND: The 5-lipoxygenase (5-LO) pathway and the chemokine CCL3 are involved in the inflammatory processes of atherosclerosis. Statins have shown cholesterol-independent pleiotropic effects on antiimmune and antiinflammatory responses in atherosclerosis. We postulated that this effect may be associated with the 5-LO pathway and CCL3. METHODS AND RESULTS: ApoE knockout mice were randomized into control group (normal diet), atherosclerosis group (high-cholesterol diet), and atorvastatin group (high-cholesterol diet and atorvastatin). Sixteen weeks later, aortic roots were stained with hematoxylin and eosin. Total cholesterol and low-density lipoprotein cholesterol were measured by the enzymatic methods. The gene and protein expressions of 5-LO and CCL3 were detected separately through real-time reverse transcription polymerase chain reaction and western blotting analyses. The serum levels of leukotriene B4 and leukotriene D4 were measured by enzyme-linked immunosorbent assay. All mice have atherosclerotic plaques, mice in the control group have only tiny atherosclerotic plaques, but mice in the atherosclerosis group and atorvastatin group have typical atherosclerotic plaques. The corrected plaque areas (plaque area/luminal area) of the aortas of mice in the atorvastatin group were significantly decreased compared with those of the atherosclerosis group. The serum cholesterol levels of the atorvastatin group were not of significant difference compared with those of the atherosclerosis group. The gene and protein expressions of 5-LO and CCL3 in the aortas, as well as the serum levels of leukotriene B4 and leukotriene D4 in atorvastatin group, were markedly reduced compared with those of the atherosclerosis group. CONCLUSION: These data suggested that atorvastatin significantly alleviated atherosclerotic lesions by inhibiting the 5-LO pathway and down regulating the expression of CCL3 in ApoE-/- mice.


Asunto(s)
Aorta/efectos de los fármacos , Araquidonato 5-Lipooxigenasa/metabolismo , Quimiocina CCL3/metabolismo , Regulación hacia Abajo/efectos de los fármacos , Ácidos Heptanoicos/uso terapéutico , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Placa Aterosclerótica/prevención & control , Pirroles/uso terapéutico , Animales , Anticolesterolemiantes/uso terapéutico , Aorta/inmunología , Aorta/metabolismo , Aorta/patología , Apolipoproteínas E/genética , Apolipoproteínas E/metabolismo , Araquidonato 5-Lipooxigenasa/química , Araquidonato 5-Lipooxigenasa/genética , Aterosclerosis/tratamiento farmacológico , Aterosclerosis/inmunología , Aterosclerosis/metabolismo , Aterosclerosis/patología , Atorvastatina , Quimiocina CCL3/antagonistas & inhibidores , Quimiocina CCL3/genética , Colesterol en la Dieta/efectos adversos , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Leucotrienos/sangre , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Distribución Aleatoria , Transducción de Señal/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...